Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headquartered in Redwood City, California.
Show more...
FAQ
Target Healthcare REIT 今天的股价是多少?▼
37Z.F 当前价格为 €1.16 EUR,过去 24 小时上涨了 +0.87%。在图表上更密切关注 Target Healthcare REIT 股价表现。
Target Healthcare REIT 的股票代码是什么?▼
根据交易所不同,股票代码可能会有所不同。例如,在 交易所,Target Healthcare REIT 的股票以代码 37Z.F 进行交易。
Target Healthcare REIT 去年的营收是多少?▼
Target Healthcare REIT 去年的营收为 0EUR。
Target Healthcare REIT 去年的净利润是多少?▼
37Z.F 去年的净收益为 -106.94MEUR。
Target Healthcare REIT 会发放股息吗?▼
是的,37Z.F 的股息每 每季度 发放一次。每股最新股息为 0.02 EUR。截至今日,股息率(FWD)% 为 5.97%。
Target Healthcare REIT 有多少名员工?▼
截至五月 26, 2026,公司共有167名员工。
Target Healthcare REIT 属于哪个行业?▼
Target Healthcare REIT从事于健康与养生行业。
Target Healthcare REIT 何时完成拆股?▼
Target Healthcare REIT 最近没有进行任何拆股。